76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
ANI Pharmaceuticals Inc
Open
SectorHealthcare
61.32 2.4
Overview
Share price change
24h
Min
59.55
Max
61.53
Income | 26M 16M |
|---|---|
Sales | 6.5M 197M |
P/E Sector Avg | 50.13 51.198 |
EPS | 0.69 |
Profit margin | 7.955 |
Employees | 897 |
EBITDA | 36M 51M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +41.95% upside |
Next Earnings | 5 Aug 2025 |
|---|
Market Cap | 91M 1.3B |
|---|---|
Previous open | 58.92 |
Previous close | 61.32 |
News Sentiment
By Acuity
44%
56%
157 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
ANI Pharmaceuticals Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
ANI Pharmaceuticals Inc Forecast
Price Target
By TipRanks
41.95% upside
12 Months Forecast
Average 85 USD 41.95%
High 94 USD
Low 79 USD
Based on 8 Wall Street analysts offering 12 month price targets forANI Pharmaceuticals Inc - Dist in the last 3 months.
Sentiment
By Acuity
157 / 380 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.
